Lionheart Health Files Patent for Bioelectric-Enhanced Klotho Nanoflowers Platform Targeting Aging Reversal

Lionheart Health, Inc. announced the filing of a non-provisional U.S. patent covering its Bioelectric-Enhanced Klotho Nanoflowers platform for aging reversal and healthspan extension. The therapeutic system combines nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging. The patented platform centers on engineered "nanoflowers"—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein shown to improve brain, kidney, cardiovascular, and metabolic health. These nanoflowers restore mitochondrial function by enhancing ATP production and reducing oxidative stress while delivering targeted bioactive agents including peptides, plasmids, mRNA, and CRISPRa activators. They also act as nanozyme catalysts that reduce reactive oxygen species and improve cellular resilience.

According to Howard J. Leonhardt, Founder, Lead Inventor and Chief Executive Officer of Lionheart Health, this invention represents the convergence of three powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation. The company's goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably. The nanoflowers are specifically engineered to respond to bioelectric fields, with signals increasing cellular uptake of nanoflowers, intracellular transport, and activation of the nanoflower's catalytic and genetic payloads. Bioelectric stimulation is applied to open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release. Klotho expression increases due to both nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter and epigenetic pathways, demonstrating a combined therapeutic benefit mechanism.

Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation, stated that bioelectric-enhanced Klotho nanoflowers provide a programmable, multi-modal tool to address the root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity. The platform is designed for system-wide healthspan improvement through mitochondrial biogenesis, reduction of cellular senescence, and stabilization of biological age markers. The patent filing adds to Lionheart Health's growing intellectual property portfolio spanning bioelectric-controlled protein expression, stem-cell mobilization and tissue regeneration, mitochondrial restoration technologies, Klotho-based gene therapy and peptide therapeutics, and regenerative aesthetic and wellness platforms. The company is currently preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics and plans to integrate the technology into its XPRIZE Healthspan competition program.

Klotho is widely recognized as one of the most promising longevity molecules ever discovered, with decreased levels associated with accelerated aging, cognitive decline, inflammation, vascular calcification, kidney dysfunction, and frailty. Lionheart's platform advances this science by enabling targeted Klotho delivery and activation inside mitochondrial and cellular compartments most responsible for aging. The technology incorporates several proprietary Lionheart technologies including BodStim™, BrainBand™, HairCell™, and advanced Klotho-based peptides and gene-expression tools. This development matters because it represents a significant advancement in targeting the fundamental mechanisms of aging at the cellular level, potentially offering a non-invasive approach to extending healthspan and addressing age-related diseases. The implications include potential new therapeutic pathways for conditions linked to aging, from cognitive decline to cardiovascular dysfunction, while the integration of bioelectric signaling with nanotechnology and Klotho modulation could establish new standards in longevity medicine. The platform's multi-modal approach addresses multiple aging drivers simultaneously, which could lead to more comprehensive healthspan interventions compared to single-target therapies.